Ogorek Anthony Joseph’s Adaptimmune Therapeutics ADAP Stock Holding History

Ogorek Anthony Joseph’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,000	Closed	-$11K	–	155
2018 Q2	$11K	Hold	1,000	–	–	0.01%	80
2018 Q1	$11K	Hold	1,000	–	–	0.01%	75
2017 Q4	$6K	Hold	1,000	–	–	﹤0.01%	90
2017 Q3	$8K	Hold	1,000	–	–	0.01%	44
2017 Q2	$4K	Hold	1,000	–	–	﹤0.01%	48
2017 Q1	$5K	Hold	1,000	–	–	0.01%	48
2016 Q4	$7K	Hold	1,000	–	–	0.01%	53
2016 Q3	$7K	Hold	1,000	–	–	0.01%	53
2016 Q2	$8K	Hold	1,000	–	–	0.01%	54
2016 Q1	$8K	Hold	1,000	–	–	0.01%	50
2015 Q4	$12K	Hold	1,000	–	–	0.01%	52
2015 Q3	$12K	Hold	1,000	–	–	0.01%	43
2015 Q2	$18K	Buy	+1,000	New	+$17.2K	0.01%	44

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Ogorek Anthony Joseph's ADAP Position: Q3 2018 in Review

Ogorek Anthony Joseph sold out of Adaptimmune Therapeutics (ADAP) in Q3 2018, closing a stake of 1,000 shares — an estimated $11K sold.

Ogorek Anthony Joseph first reported a position in ADAP in Q2 2015 and held it in 13 quarters. The position peaked at $18K in Q2 2015. 93 funds tracked by Wall St. Rank hold ADAP as of Q3 2018.

Ogorek Anthony Joseph reported no remaining Adaptimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
Ogorek Anthony Joseph sold 1,000 Adaptimmune Therapeutics shares in Q3 2018, an estimated $11K.
Ogorek Anthony Joseph first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 13 quarters.
Ogorek Anthony Joseph's Adaptimmune Therapeutics position peaked at $18K in Q2 2015.
93 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2018.

Based on Ogorek Anthony Joseph's 13F filing for Q3 2018, filed 17 Oct 2018.